Ferrer is an international pharmaceutical company, headquartered in Barcelona with a presence in more than 90 countries. Our mission is to advance the wellbeing of society.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

PR Newswire | February 03, 2020

news image

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause more patient deaths every year than breast, prostate, and colorectal cancer. With Angelini's new portfolio, designed to be used across the care continuum, they are addressing the "why" behi...

Read More

Business Insights

PRIME MEDICINE EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS TO SUPPORT CONTINUED GROWTH AND ADVANCEMENT OF PRIME EDITING TECHNOLOGY AND PORTFOLIO

Prime Medicine | July 29, 2022

news image

Prime Medicine, Inc. a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying Prime Editing technology “Prime Medicine is advancing a first-of-its-kind technology intended to expand the number of patients who may benefit from genetic medicines. We are thrilled to welcome Richard, Niamh and Fubao to the team. Together, they bri...

Read More

CNS PHARMACEUTICALS ANNOUNCES US DRUG MANUFACTURING MILESTONES

CNS Pharmaceuticals | September 03, 2020

news image

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and eng...

Read More

Business Insights

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

news image

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More
news image

ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

PR Newswire | February 03, 2020

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause more patient deaths every year than breast, prostate, and colorectal cancer. With Angelini's new portfolio, designed to be used across the care continuum, they are addressing the "why" behi...

Read More
news image

Business Insights

PRIME MEDICINE EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS TO SUPPORT CONTINUED GROWTH AND ADVANCEMENT OF PRIME EDITING TECHNOLOGY AND PORTFOLIO

Prime Medicine | July 29, 2022

Prime Medicine, Inc. a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying Prime Editing technology “Prime Medicine is advancing a first-of-its-kind technology intended to expand the number of patients who may benefit from genetic medicines. We are thrilled to welcome Richard, Niamh and Fubao to the team. Together, they bri...

Read More
news image

CNS PHARMACEUTICALS ANNOUNCES US DRUG MANUFACTURING MILESTONES

CNS Pharmaceuticals | September 03, 2020

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and eng...

Read More
news image

Business Insights

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us